Back to Interventions
Substance / Medication

Tolbutamide

SNOMED 373481003UMLS C0040374

Overview

Active Ingredient
tolbutamide
RxNorm CUI
10635

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Diabetes mellitus type II

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Creatinine

LOINC 2160-0

secondary

Sodium

LOINC 2951-2

secondary

Glucose

LOINC 2345-7

primary

Hemoglobin A1c

LOINC 4549-2

primary

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
0
With Results

Recent Trials

Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects

NCT02291666Phase 4Completed73 enrolled

A Pharmacokinetic Evaluation of Metformin in Relation to the Polymorphism A270S in Healthy Caucasian Volunteers

NCT01237522Phase 4Completed50 enrolled
View all 2 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Microdose pharmacogenetic study of ¹⁴C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism.
Ikeda Toshihiko, Aoyama Shinsuke, Tozuka Zenzaburo et al. · Eur J Pharm Sci · 2013
PMID: 23727057RCT
Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteers.
Teng Renli, Mitchell Patrick, Butler Kathleen · Int J Clin Pharmacol Ther · 2013
PMID: 23380426RCT
Validation of a sensitive UHPLC-MS/MS method for cytochrome P450 probe substrates caffeine, tolbutamide, dextromethorphan, and alprazolam in human serum reveals drug contamination of serum used for research.
Chen Luying, van Breemen Richard B · J Pharm Biomed Anal · 2020
PMID: 31744669ObservationalFull text (PMC)
Pharmacokinetics and metabolic elimination of tolbutamide in female rats: Comparison with male rats.
Fukuno Shuhei, Nagai Katsuhito, Horii Ayano et al. · Biopharm Drug Dispos · 2018
PMID: 29978919Observational
Subtle structural changes in the Asp251Gly/Gln307His P450 BM3 mutant responsible for new activity toward diclofenac, tolbutamide and ibuprofen.
Di Nardo Giovanna, Dell'Angelo Valentina, Catucci Gianluca et al. · Arch Biochem Biophys · 2016
PMID: 26718083Observational
Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats.
Ma Jianshe, Wang Shuanghu, Zhang Meiling et al. · Biomed Chromatogr · 2015
PMID: 25582505Observational
Tolbutamide controls glucagon release from mouse islets differently than glucose: involvement of K(ATP) channels from both α-cells and δ-cells.
Cheng-Xue Rui, Gómez-Ruiz Ana, Antoine Nancy et al. · Diabetes · 2013
PMID: 23382449ObservationalFull text (PMC)
Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx.
Jarrard Rachel E, Wang Yuchen, Salyer Amy E et al. · Mol Pharmacol · 2013
PMID: 23071106ObservationalFull text (PMC)
Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam, and midazolam in adenoviral cytochrome P450-transfected HepG2 cells and comparison with hepatocytes and in vivo.
Donato M Teresa, Hallifax David, Picazo Laura et al. · Drug Metab Dispos · 2010
PMID: 20501911Observational
Simultaneous HPLC determination of tolbutamide, phenacetin and their metabolites as markers of cytochromes 1A2 and 2C6/11 in rat liver perfusate.
Jurica Jan, Konecný Jirí, Zahradníková Lucia Zendulková et al. · J Pharm Biomed Anal · 2010
PMID: 20149568Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Family Medicine Physician

Family Medicine

NUCC 207Q00000X
Internal Medicine Physician

Internal Medicine

NUCC 207R00000X
Endocrinology, Diabetes & Metabolism Physician

Internal Medicine — Endocrinology, Diabetes & Metabolism

NUCC 207RE0101X
Find a Provider

Health Goals

Goals connected through associated conditions

Monitor Blood SugarOptimize Metabolic Function

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tolbutamide (substance)
SNOMED CT
373481003
UMLS CUI
C0040374
RxNorm CUI
10635

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

1
Conditions
4
Biomarkers
3
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.